Literature DB >> 10472357

Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer.

P L Moser1, L Hefler, C Tempfer, W Neunteufel, D G Kieback, G Gitsch.   

Abstract

BACKGROUND: Matrix metalloproteinases (MMPs) are a family of zinc-dependent metalloendopeptidases which participate in the degradation of collagen and other extracellular matrix macromolecules. Expression of gelatonic MMPs, such as MMP-2 has been linked to enhanced tumor invasion and metastasis in in vitro and in vivo model systems. It was the aim of this study to determine whether the expression of MMP-1, MMP-2, and TIMP-2 correlates with survival in patients with surgically treated endometrial cancer.
METHOD: A sample of 103 paraffin-embedded tumor specimens of surgical treated endometrial cancer was immunohistochemically investigated.
RESULTS: MMP-1, MMP-2, and TIMP-2 were detected by immunohistochemistry in 95% (98/103), 87% (89/103), and 80% (82/103) of the tumour samples, respectively. Correlation coefficients for MMP-1/MMP-2, MMP-1/TIMP-2, MMP-2/TIMP-2 were 0.28 (p = 0.004), 0.05 (p = 0.6), and -0.03 (p = 0.73), respectively. In the univariate analysis, the expression of MMP-1 (log-rank test, p = ns), MMP-2 (log-rank test, p = ns), and TIMP-2 (log-rank test, p = ns) were not associated with overall survival.
CONCLUSION: MMP-1, MMP-2, and TIMP-2, detected by immunohistochemistry are not helpful in predicting the prognosis of endometrial cancer patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10472357

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Relationship between matrix metalloproteinase 2 and lung cancer progression.

Authors:  Chun-Bao Guo; Shan Wang; Chun Deng; Dian-Liang Zhang; Fu-Ling Wang; Xian-Qing Jin
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

2.  Expression of matrix metalloproteinase-2 and survivin in endometrioid and nonendometrioid endometrial cancers and clinicopathologic significance.

Authors:  Evren Yilmaz; Meral Koyuncuoglu; Ilknur Bilkay Görken; Emre Okyay; Bahadir Saatli; Emine Cagnur Ulukus; Ugur Saygili
Journal:  J Gynecol Oncol       Date:  2011-06-30       Impact factor: 4.401

3.  Immunoreactivity for TIMP-2 is associated with a favorable prognosis in endometrial carcinoma.

Authors:  Maria Honkavuori-Toivola; Anne Talvensaari-Mattila; Ylermi Soini; Taina Turpeenniemi-Hujanen; Markku Santala
Journal:  Tumour Biol       Date:  2012-01-21

4.  Combination of strong MMP-2 and weak TIMP-2 immunostainings is a significant prognostic factor in endometrial carcinoma.

Authors:  Maria Honkavuori-Toivola; Markku Santala; Ylermi Soini; Taina Turpeenniemi-Hujanen; Anne Talvensaari-Mattila
Journal:  Dis Markers       Date:  2013       Impact factor: 3.434

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.